Knight Therapeutics Inc. (TSX:GUD)
Canada · Delayed Price · Currency is CAD 9.66
+0.03 (0.31%)
Aug 21, 2026, 4:00 PM EST
Knight Therapeutics Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 547.31 | 450.09 | 371.3 | 328.2 | 293.56 | 243.48 | |
Revenue Growth | 42.32% | 21.22% | 13.13% | 11.80% | 20.57% | 22.03% |
Cost of Revenue | 288.05 | 249.86 | 196.9 | 175.55 | 155.5 | 128.07 |
Gross Profit | 259.26 | 200.23 | 174.41 | 152.65 | 138.06 | 115.41 |
Selling, General & Admin | 142.02 | 124.11 | 99.35 | 83.69 | 88.62 | 74.38 |
Research & Development | 37.89 | 28.98 | 23.3 | 17.55 | 14.76 | 12.69 |
Amortization of Goodwill & Intangibles | 57.41 | 49.49 | 44.36 | 45.04 | 51.74 | 41.18 |
Operating Expenses | 237.32 | 202.58 | 167.01 | 146.28 | 155.12 | 128.24 |
Operating Income | 21.93 | -2.35 | 7.4 | 6.37 | -17.06 | -12.83 |
Interest Expense | -11.06 | -10.42 | -9.22 | -12.49 | -6.6 | -3.62 |
Interest & Investment Income | 4.18 | 6.21 | 10.41 | 12.58 | 10.63 | 7.38 |
Currency Exchange Gain (Loss) | 3.26 | 1.86 | -4.19 | -15.17 | 7.44 | -3.74 |
Other Non Operating Income (Expenses) | 3.75 | -2.27 | 0.23 | 12.3 | -22.68 | 19.07 |
EBT Excluding Unusual Items | 22.06 | -6.98 | 4.62 | 3.58 | -28.27 | 6.27 |
Merger & Restructuring Charges | 4.46 | - | - | - | - | - |
Gain (Loss) on Sale of Investments | -7.36 | -2.34 | -11.79 | -19.62 | - | - |
Asset Writedown | - | - | - | -9.26 | -23.98 | - |
Other Unusual Items | 2.22 | 2.62 | 9.23 | 3.3 | 8.29 | 0.42 |
Pretax Income | 21.39 | -6.7 | 2.05 | -21.99 | -43.96 | 6.69 |
Income Tax Expense | 6.52 | -1.33 | -2.28 | -5.15 | -14.07 | -8.99 |
Earnings From Continuing Operations | 14.87 | -5.37 | 4.33 | -16.84 | -29.89 | 15.68 |
Net Income | 14.87 | -5.37 | 4.33 | -16.84 | -29.89 | 15.68 |
Net Income to Common | 14.87 | -5.37 | 4.33 | -16.84 | -29.89 | 15.68 |
Net Income Growth | 3782.77% | - | - | - | - | -62.74% |
Shares Outstanding (Basic) | 99 | 100 | 101 | 107 | 115 | 124 |
Shares Outstanding (Diluted) | 99 | 100 | 101 | 107 | 115 | 125 |
Shares Change | -1.29% | -1.84% | -5.61% | -6.46% | -7.74% | -5.66% |
EPS (Basic) | 0.15 | -0.05 | 0.04 | -0.16 | -0.26 | 0.13 |
EPS (Diluted) | 0.15 | -0.05 | 0.04 | -0.16 | -0.26 | 0.13 |
EPS Growth | 8835.08% | - | - | - | - | -60.55% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 110.36 | 67.05 | 33.81 | 34.99 | 42.12 | 40.79 |
Free Cash Flow Per Share | 1.11 | 0.67 | 0.33 | 0.33 | 0.37 | 0.33 |
Gross Margin | 47.37% | 44.49% | 46.97% | 46.51% | 47.03% | 47.40% |
Operating Margin | 4.01% | -0.52% | 1.99% | 1.94% | -5.81% | -5.27% |
Profit Margin | 2.72% | -1.19% | 1.17% | -5.13% | -10.18% | 6.44% |
Free Cash Flow Margin | 20.16% | 14.90% | 9.11% | 10.66% | 14.35% | 16.75% |
EBITDA | 81.16 | 49.4 | 55.96 | 53.26 | 40.98 | 32.46 |
EBITDA Margin | 14.83% | 10.98% | 15.07% | 16.23% | 13.96% | 13.33% |
D&A For EBITDA | 59.23 | 51.75 | 48.56 | 46.89 | 58.04 | 45.29 |
EBIT | 21.93 | -2.35 | 7.4 | 6.37 | -17.06 | -12.83 |
EBIT Margin | 4.01% | -0.52% | 1.99% | 1.94% | -5.81% | -5.27% |
Effective Tax Rate | 30.46% | - | - | - | - | - |